Axovant Sciences

http://www.axovant.com/

Last activity: 06.10.2017

Probably Closed - Reference to Sio Gene Therapies

Categories: GamingOnlinePlatformProduct

TanganSakti99 adalah platform slot online gacor 2025 terpercaya yang juga menyediakan voucher game digital terlengkap. Mainkan slot RTP tinggi dan klaim bonus menarik setiap hari!

Mentions

Overview

Location

Switzerland

Employees

51-200

Founded date

2014

Investors 1

Date	Name	Website
Sign up to see	Sign up to see	Sign up to see

Mentions in press and media 15

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Sep 26, 2017	Roivant receives bad news — and so does SoftBank	Last month, SoftBank, through its massive Vision Fund, led the single biggest private financing round for a healthcare company ever — funneling $1.1 billion into the drug holding outfit Roivant Sciences. Today, the Japanese conglomerate mig...
Aug 9, 2017	Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank	Roivant Sciences, a three-year-old, Basel, Switzerland-based company aiming to one day be a giant holding company for dozens of independent biopharmaceutical companies, has raised $1.1 billion in equity led by the SoftBank Vision Fund — mak...
Apr 10, 2017	Axovant hires ex-Medivation CEO as it nears Phase 3 Alzheimer’s readout	That pipeline and commercialization experience could go a long way at Axovant. Indeed, Wall Street seemed pleased with the announcement. Axovant shares surged 27 percent on Monday morning following the news. Ramaswamy, a 31-year-old former ...
Jan 30, 2017	The Phase 3 Alzheimer’s company few have heard of	The company had two lucky breaks, which, ironically have in some ways backfired in terms of awareness and credibility. The first is that its active compound didn’t require lengthy clinical trials. As a result, many wrote it off as an unprov...
Jan 13, 2017	Weekly Roundup: Claims surface on Trump’s dealings with Russia, Yahoo splits into Altaba	As part of the Verizon acquisition, Yahoo has split itself into an investment unit called Altaba and is now waiting for Verizon to undertake its remaining assets. Amazon announced a plan to create 100,000 U.S. jobs, and memos about Trump’s ...
Jan 6, 2017	The billion-dollar pharma startup that Silicon Valley has totally missed	When it comes to millennials and healthcare companies, recent history gives plenty of reason for pause. Elizabeth Holmes, the founder and CEO of Theranos, has watched her star fall precipitously over the last year, amid a continuing drumbea...
Dec 29, 2016	Ambitious young biotech group establishes global headquarters in Basel
Oct 27, 2016	Myovant Sciences rallies $218 million biotech IPO	At the heart of Myovant’s impressive stock price is an agreement with Takeda Pharmaceuticals, which traded global rights to its small molecule relugolix for minority shares in the company and future royalties. Takeda will retain commercial ...
Jun 29, 2016	The biotech IPO feast flags as investors lose their appetite for R&D risk	There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund...
Jun 12, 2015	Axovant Sciences IPO generates $2B+ valuation, NIH program tracks molecules affected by physical activity (Morning Read)	Given the fact that GlaxoSmithKline had a chance to take a look at this drug in the clinic, and concluded that they couldn’t do better than selling it for lunch money, the IPO terms illustrate the kind of overnight riches a select few can f...
	Axovant hires ex-Medivation CEO as it nears Phase 3 Alzheimer’s readout	Five months out from a potentially pivotal data readout on its lead candidate for Alzheimer’s disease, Axovant founder Vivek Ramaswamy has taken a step back, handing the reins to highly-experienced biopharma CEO David Hung. Hung founded Med...
	Axovant Sciences IPO generates $2B+ valuation, NIH program tracks molecules affected by physical activity (Morning Read)	TOP STORIES Axovant Sciences, which has an Alzheimer’s disease drug in Phase 3 development, raised $315 million — generating a valuation of more than $2 billion in its first day of trading on the New York Stock Exchange — the largest IPO in...
	Myovant Sciences rallies $218 million biotech IPO	As the nation slept, women’s health company Myovant Sciences quietly completed the largest biotech initial public offering (IPO) of 2016, amassing $218 million on the New York Stock Exchange. Shares will trade under the ticker symbol (NYSE:...
	The Phase 3 Alzheimer’s company few have heard of	A ketone strip used to measure levels of ketone bodies in the patient’s system In a field dominated by Big Pharma and clinical trials that cost tens of millions of dollars, one small private company has made it all the way to Phase 3 trials...

Reviews 0

FAQ about Axovant Sciences

When was Axovant Sciences founded?

Axovant Sciences was founded in 2014.

What has the press written about Axovant Sciences?

Parsers VC has collected 15 articles mentioning Axovant Sciences, among them “Roivant receives bad news — and so does SoftBank” (Sep 26, 2017) and “Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank” (Aug 9, 2017).

Is Axovant Sciences still active?

Axovant Sciences is probably closed: its latest activity on Parsers VC dates from Oct 6, 2017.